Results 41 to 50 of about 242,337 (233)

Comparison of topical application of TSG-6, cyclosporine, and prednisolone for treating dry eye

open access: yes, 2016
Purpose: To compare the therapeutic effects of topical tumor necrosis factor (TNF)-alpha-stimulated gene/protein-6 (TSG-6) with those of cyclosporine and prednisolone eye drops in NOD.B10.H2(b) mice, a model for inflammation-mediated dry eye.
Kim, Yu Jeong   +7 more
core   +1 more source

A ROS‐Responsive and Mucoadhesive Thermosensitive Hydrogel Encapsulated with Mizoribine for Synergistic Dry Eye Therapy

open access: yesAdvanced Science, EarlyView.
The ROS‐responsive in situ thermosensitive MZR@SPPP hydrogel system enables dual‐stage drug loading and sustained ocular delivery. Upon administration, it gelates at ocular surface temperature, enhancing ocular adhesion. By scavenging free radicals, restoring NRF2‐mediated antioxidant defense and mitochondrial homeostasis, and suppressing inflammatory ...
Danyi Qin   +13 more
wiley   +1 more source

Dual‐Dynamically Crosslinked Nanogels Enable Prolonged Ocular Retention for Multimodal Dry Eye Therapy

open access: yesAdvanced Science, EarlyView.
This berberine‐loaded dual‐dynamically crosslinked nanogel integrates tannic acid‐zinc metal‐phenolic networks and carboxymethyl chitosan/aldehyde‐functionalized poly(ethylene glycol) dynamic Schiff base networks, achieving 1‐year colloidal and antioxidant stability, sustained corneal berberine exposure for 24 h to support convenient once‐daily dosing,
Yanru Xin   +7 more
wiley   +1 more source

Current evidence and insights on single vs. double dose of basiliximab in adult solid organ transplant recipients: A systematic review

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim The aim of this systematic review was to assess all available clinical data regarding the use of a single dose of basiliximab in solid organ transplantation compared to the standard double dosage, with particular interest in efficacy, safety and cost‐savings.
Alessio Provenzani   +4 more
wiley   +1 more source

When Treatment Meets Natural History: Understanding Early Dermatitis‐Related Adverse Events in Systemic Atopic Dermatitis Trials

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Biologics and Janus kinase (JAK) inhibitors have transformed the management of atopic dermatitis (AD), yet some patients experience early worsening of disease activity during treatment initiation. In clinical trials, these events are typically recorded as treatment‐emergent adverse events (TEAEs), most commonly coded as “atopic dermatitis”. We
Diego Ruiz Dasilva   +17 more
wiley   +1 more source

Topical Use of Cyclosporine in the Treatment of Vernal Keratoconjunctivitis

open access: yesAmerican Journal of Ophthalmology, 1990
We treated 11 patients with vernal keratoconjunctivitis for four to nine months with topical cyclosporine as a 2% dilution in castor oil. No significant side effects occurred, except for mild and transient burning upon administration. Within the first 15 days, both symptoms and signs of the condition improved significantly, and these results were ...
SECCHI AG, TOGNON MS, LEONARDI, ANDREA
openaire   +2 more sources

Nail Psoriasis in Pediatric Populations

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Pediatric nail psoriasis is an under‐recognized yet clinically important manifestation of psoriasis with both diagnostic and prognostic implications. Nail involvement in children is associated with greater overall disease severity, poorer treatment outcomes, and is a predictor for the development of psoriatic arthritis.
Aditya K. Gupta   +3 more
wiley   +1 more source

Effective Treatment with Topical Cyclosporine of a Child with Steroid-Dependent Interstitial Keratitis

open access: yes, 2008
Purpose To report a case of steroid-dependent idiopathic interstitial keratitis in a child successfully treated with topical cyclosporine 2% drops. Methods Case report.
E. Miserocchi   +5 more
core   +1 more source

Real World Use of the IL‐36 Receptor Antagonist Spesolimab: A Systematic Review and Analysis

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Spesolimab, an interleukin‐36 receptor antagonist, is approved for the treatment and prevention of generalised pustular psoriasis (GPP) flares. Its use has increasingly been reported in real‐world settings for both GPP and other inflammatory dermatoses.
Sophia A. Mense   +4 more
wiley   +1 more source

Cutaneous complications of cyclosporine: a case of drug-induced folliculitis in atopic dermatitis

open access: yesDermatology Reports
Cyclosporine-induced folliculitis remains underreported and underrecognized in clinical practice, posing diagnostic challenges for dermatologists and clinicians. In this case report, we present a compelling case of cyclosporine-induced folliculitis.
Mohammad Al-Haddab   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy